Sullivan Nicholaides Pathology, Brisbane, Qld, Australia.
Pathology. 2017 Oct;49(6):568-574. doi: 10.1016/j.pathol.2017.07.003. Epub 2017 Aug 23.
Merkel cell carcinoma (MCC) is a rarely made but potentially devastating diagnosis. While local disease might be cured by surgery and radiotherapy, advanced disease is usually rapidly progressive and fatal. Until very recently, the only approach to metastatic MCC was cytotoxic chemotherapy with results so disappointing that current treatment guidelines discourage its use and recommend clinical trial as a more viable treatment option. Fortunately, recent advances in the understanding of the molecular pathogenesis of this tumour have produced a wide variety of experimental treatments for MCC, some of which are quite promising. The most current information regarding the diagnosis, staging, management of this tumour is briefly presented as well as new insights into the molecular basis of MCC and therapeutic approaches to MCC.
默克尔细胞癌(Merkel cell carcinoma,MCC)是一种罕见但潜在致命的诊断。虽然局部疾病可以通过手术和放射治疗治愈,但晚期疾病通常进展迅速且致命。直到最近,转移性 MCC 的唯一治疗方法是细胞毒性化疗,但结果令人失望,因此目前的治疗指南不鼓励使用这种方法,建议临床试验作为更可行的治疗选择。幸运的是,对这种肿瘤分子发病机制的理解的最新进展为 MCC 提供了各种实验性治疗方法,其中一些方法非常有前途。本文简要介绍了这种肿瘤的诊断、分期和治疗管理的最新信息,以及对 MCC 分子基础和治疗方法的新见解。